Effect of the new selective COMT inhibitor CGP 28014 A on the formation of 3-O-methyldopa (3OMD) in plasma of healthy subjects
CGP 28 014 A is a specific inhibitor of catechol-O-methyl transferase (COMT). The effect on COMT was assessed with the levodopa test in 5 unmedicated subjects and after pretreatment with 200–600 mg CGP 28 014 p.o. Plasma concentrations of DOPA, 3-O-methyldopa (3OD), 3,4-dihydroxyphenylacetic acid (DOPAC) and homovanillic acid were measured. CGP 28 014 A decreased 3OMD not dose-related by 67% (p < 0.05). This, and an increase of DOPAC shows COMT inhibition by this compound in humans.
KeywordsHomo Vanillic Acid COMT Inhibitor Measure Plasma Concentration Levodopa Test Specific HPLC Method
Unable to display preview. Download preview PDF.
- Cotzias GC, Papvasiliou PS, Ginos JZ, Tolosa ES (1975) Treatment of Parkinson’s disease and allied conditions. In: Tower DB (ed) The nervous system, vol 2. The clinical neurosciences. Raven Press, New York, pp 323–329.Google Scholar
- Maennistoe PT, Kaakkola S (1989) New selective COMT inhibitors: useful adjuncts for Parkinson’s disease?. TIPS 10:54–56.Google Scholar
- Waldmeier PC, Feldrauer J-J, Hauser K, Bittiger H, Bischoff S, von Sprecher G (1990) CGP 28 014 A, a new non-catecholic COMT inhibitor. Naunyn-Schmie-debergs Arch Pharmacol 386 [Suppl]: R97.Google Scholar